Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome (ZEPHYR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03790865 |
|
Recruitment Status :
Terminated
(Livoletide did not result in a statistically significant improvement in hyperphagia and food-related behaviors)
First Posted : January 2, 2019
Results First Posted : February 17, 2021
Last Update Posted : February 17, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Prader-Willi Syndrome Hyperphagia | Drug: Livoletide Drug: Placebo | Phase 2 Phase 3 |
The protocol includes 2 consecutive parts:
- The first part is a Phase 2b dose-response study consisting of a 3-month double-blind, placebo-controlled Core Period followed by a 9-month Extension Period.
- The second part is a Phase 3 study consisting of a 6-month double-blind, placebo-controlled Core Period followed by a 6-month Extension Period. Phase 3 may be initiated following review of safety and efficacy results at the completion of the Phase 2b Core Period.
A total of approximately 50 patients per group (8 to 65 years of age) will be randomized (approximately 150 patients in total). In addition to this cohort of 150 patients, a separate cohort of patients 4 to 7 years of age will also be randomized.
Note: The 8-65 year old cohort has been fully enrolled. Enrollment into the 4-7 year age cohort remains ongoing.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 158 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analogue, on Food-related Behaviors in Patients With Prader-Willi Syndrome |
| Actual Study Start Date : | March 25, 2019 |
| Actual Primary Completion Date : | February 26, 2020 |
| Actual Study Completion Date : | May 25, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Low-Dose Livoletide
Daily subcutaneous injection of ~ 60 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
|
Drug: Livoletide
Daily subcutaneous injection
Other Name: AZP-531 |
|
Experimental: High-Dose Livoletide
Daily subcutaneous injection of ~120 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
|
Drug: Livoletide
Daily subcutaneous injection
Other Name: AZP-531 |
|
Placebo Comparator: Placebo
Daily subcutaneous injection of 0.9% NaCl for the 3 month double-blind core period and then low-dose or high-dose livoletide for 9 month open label extension period.
|
Drug: Placebo
Daily subcutaneous injection |
- Change in Hyperphagia and Food-related Behaviors (Hyperphagia Questionnaire for Clinical Trials; HQ-CT) [ Time Frame: Baseline to month 3 ]Change from baseline to the end of the 3-month Core Period for HQ-CT total score. The HQ-CT score range is 0 to 36 where the higher score represents more severe abnormal food related behaviors.
- Percentage Change From Baseline to Month 3 in Total Body Fat Mass in Patients Eight to 65 Years of Age Defined as Overweight/Obese [ Time Frame: Baseline to month 3 ]
Total body fat mass was assessed using dual energy X-ray absorptiometry (DXA) scan. DXAs were conducted at each local facility using standardized procedures and settings.
Overweight/obese patients were defined as follows:
- patients ≥18 years of age: BMI ≥27 kg/m2
- patients 4-17 years of age: BMI ≥90th percentile for the same age and sex
- Change From Baseline to Month 3 in Waist Circumference in Patients Eight to 65 Years of Age Defined as Overweight/Obese [ Time Frame: Baseline to month 3 ]
The waist circumference was measured in fasting condition at the superior border of iliac crest, according to recommendations from the Anthropometry Procedures Manual of the National Health and Nutrition Examination Survey, Revised 2007.
Overweight/obese patients were defined as follows:
- patients ≥18 years of age: BMI ≥27 kg/m2
- patients 4-17 years of age: BMI ≥90th percentile for the same age and sex
- Percentage Change From Baseline to Month 3 in Body Weight in Patients Eight to 65 Years of Age Defined as Overweight/Obese [ Time Frame: Baseline to month 3 ]
Patients were weighed in fasting condition, clothed (underwear, light gown or light clothing), without footwear or heavy jewelry, using a calibrated scale. The same scale should be used throughout the study if possible. The conditions under which patients are weighed should be kept consistent if possible.
Overweight/obese patients were defined as follows:
- patients ≥18 years of age: BMI ≥27 kg/m2
- patients 4-17 years of age: BMI ≥90th percentile for the same age and sex
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 4 Years to 65 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Confirmed genetic diagnosis of PWS
- Evidence of increased appetite or hyperphagia
- Patient must have a single primary caregiver who should be available for certain durations of the study
- BMI ≤ 65 kg/m2
- Growth hormone treatment permitted if doses have been stable for at least 1 month prior to screening
Exclusion Criteria:
- History of chronic liver disease
- Type 1 diabetes mellitus
- HbA1c > 10%
- Body weight <20 kg
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03790865
Show 37 study locations
Documents provided by Millendo Therapeutics, Inc. ( Millendo Therapeutics SAS ):
| Responsible Party: | Millendo Therapeutics SAS |
| ClinicalTrials.gov Identifier: | NCT03790865 |
| Other Study ID Numbers: |
AZP01-CLI-003 |
| First Posted: | January 2, 2019 Key Record Dates |
| Results First Posted: | February 17, 2021 |
| Last Update Posted: | February 17, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Prader-Willi Syndrome PWS |
|
Prader-Willi Syndrome Syndrome Hyperphagia Disease Pathologic Processes Intellectual Disability Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases |
Abnormalities, Multiple Congenital Abnormalities Chromosome Disorders Genetic Diseases, Inborn Obesity Overweight Overnutrition Nutrition Disorders Signs and Symptoms, Digestive |